EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, PuraPharm's enterprise value is HK$701.6 Mil.
PuraPharm's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-26.3 Mil. Therefore, PuraPharm's EV-to-EBITDA for today is -26.66.
The historical rank and industry rank for PuraPharm's EV-to-EBITDA or its related term are showing as below:
HKSE:01498'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -28.89 Med: 6.27 Max: 22.75
Current: -26.66
During the past 10 years, the highest EV-to-EBITDA of PuraPharm was 22.75. The lowest was -28.89. And the median was 6.27.
HKSE:01498's EV-to-EBITDA is ranked worse than 100% of 708
companies
in the Drug Manufacturers industry
Industry Median: 14.22
vs HKSE:01498: -26.66
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-30), PuraPharm's stock price is HK$0.73.
PuraPharm's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.268. Therefore, PuraPharm's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
PuraPharm EV-to-EBITDA Historical Data
The historical data trend for PuraPharm's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of PuraPharm's EV-to-EBITDA
For the Drug Manufacturers - Specialty & Generic subindustry, PuraPharm's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PuraPharm's EV-to-EBITDA Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PuraPharm's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where PuraPharm's EV-to-EBITDA falls into.
PuraPharm EV-to-EBITDA Calculation
PuraPharm's EV-to-EBITDA for today is calculated as:
PuraPharm's current Enterprise Value is HK$701.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PuraPharm's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-26.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PuraPharm (HKSE:01498) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
PuraPharm's share price for today is HK$0.73.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PuraPharm's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.268.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of PuraPharm's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
PuraPharm Corporation Ltd is a Hong Kong-based Chinese medicine Company. It is engaged in the research and development, production, marketing and sale of concentrated Chinese medicine granules (CCMG) products marketed under the brand Nong's. In addition, the organization is engaged in rendering Chinese medical diagnostic services. The operating segments of the group are China CCMG, Hong Kong CCMG, Chinese healthcare products, Plantation and Clinics. It generates maximum revenue from the China CCMG segment mainly engages in the production and sale of CCMG products in China. The group derives revenue from the customers located in Hong Kong, Mainland China and Other countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:01498 has been successfully added to your 